Tafsure

Tafsure 25 mg (Tenofovir alafenamide) is an oral tablet used in patients with Hepatitis B viral (HBV) and HIV-1 infections. The pro-drug is highly efficient in its activities even with 10 times lower dose than its predecessor (Tenofovir disoproxil). Tafsure 25 mg (Tenofovir alafenamide) is administered in the form of a 25 mg oral dosage with food. It is taken once daily in the morning or evening.

Tafsure 25 mg (Tenofovir alafenamide) is specifically indicated against compensated (with a functional system) liver disease in adults. Plus, in combination with other anti-HBV (anti-retroviral) drugs, it can be employed in treatment-naïve HIV-1 patients. However, Tafsure 25 mg (Tenofovir alafenamide) is not recommended in HBV patients with decompensated (without a functional system) liver disease. In terms of modifications, the dosage regimen remains the same even if the patients have kidney or other liver complications.

Tafsure 25 mg (Tenofovir alafenamide) once swallowed, takes around 48 minutes to absorb in the system and after reaching the site of infection, binds efficiently with viral cells. Once the anti-viral activities are completed, more than 50% of the drug is excreted from the body in roughly 51 minutes.

Warnings and Precautions associated with Tafsure (Tenofovir alafenamide):

Missed dosage leading to resistance:

Patients should take the dosage as prescribed by their doctor. If patients miss even a single dose, the viral cells may develop resistance against (Tenofovir alafenamide).

Discontinuation of treatment leading to severe acute liver complications:

Patients are strictly prohibited to stop their current dosing schedule. The former can cause serious repercussions in the liver.

New onset or worsening condition of the kidney:

If patients have any sort of problems in the kidney, there are chances of acute kidney failure if tenofovir-based medications are used.

Risk of developing HIV-1 resistance in patients with HIV-1 coinfection:

If patients possess or develop HIV infection and haven’t received any therapy, Tafsure 25 mg (Tenofovir alafenamide)may increase the chances of developing resistance to those HIV medications.

Lactic acidosis (excessive amounts of lactic acid in the blood) and Hepatomegaly (enlarged liver): 

If patients are seen with symptoms like tiredness, weakness, pain in the muscles, stomach pain with nausea, vomiting, dizziness, short or fast breathing and heartbeats, and cold or blue hands and legs, immediately consult the doctor.

Side-effects of Tafsure 25 mg (Tenofovir alafenamide):

Tafsure 25 mg (Tenofovir alafenamide) is one of the safest anti-retroviral medicines with only one common side-effect namely headache. However, in rare cases, if the patients have severe complications in the liver, the side-effects include,

• White part of skin or eyes turning yellow
• Tea-coloured urine
• Stools in a lightish colour
• Loss of appetite
• Nausea
• Abdominal (stomach area) pain

Note: Tafsure 25 mg (Tenofovir alafenamide) might express additional side-effects too. Please discuss with your doctor for more information.